Works matching IS 01676997 AND DT 2013 AND VI 31 AND IP 4

Results: 36

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Published in:

2013

By:

Erba, Harry;
Sayar, Hamid;
Juckett, Mark;
Lahn, Michael;
Andre, Valerie;
Callies, Sophie;
Schmidt, Shelly;
Kadam, Sunil;
Brandt, John;
Bockstaele, Dirk;
Andreeff, Michael

Publication type:

Journal Article

Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons.

Published in:

2013

By:

Lu, Frank;
Yu, Ching-Chia;
Chiu, Huei-Hsuan;
Liu, Hsingjin;
Chen, Shao-Yin;
Lin, Shufan;
Goh, Ting-Yi;
Hsu, Hsin-Chih;
Chien, Chih-Han;
Wu, Han-Chung;
Chen, Ming-Shan;
Schuyler, Scott;
Hsieh, Wu-Shiun;
Wu, Mei-Hwan;
Lu, Jean

Publication type:

Journal Article

Functional and molecular characterization of kinin B and B receptors in human bladder cancer: implication of the PI3Kγ pathway.

Published in:

2013

By:

Sgnaolin, V.;
Pereira, T.;
Bogo, M.;
Zanin, R.;
Battastini, A.;
Morrone, F.;
Campos, M.

Publication type:

Journal Article

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 986, doi. 10.1007/s10637-012-9921-8

By:

Weiss, Glen;
Chao, Joseph;
Neidhart, Jeffrey;
Ramanathan, Ramesh;
Bassett, Dawn;
Neidhart, James;
Choi, Chung;
Chow, Warren;
Chung, Vincent;
Forman, Stephen;
Garmey, Edward;
Hwang, Jungyeon;
Kalinoski, D.;
Koczywas, Marianna;
Longmate, Jeffrey;
Melton, Roger;
Morgan, Robert;
Oliver, Jamie;
Peterkin, Joanna;
Ryan, John

Publication type:

Article

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 943, doi. 10.1007/s10637-012-9916-5

By:

LoConte, Noelle;
Holen, Kyle;
Schelman, William;
Mulkerin, Daniel;
Deming, Dustin;
Hernan, Hilary;
Traynor, Anne;
Goggins, Timothy;
Groteluschen, David;
Oettel, Kurt;
Robinson, Emily;
Lubner, Sam

Publication type:

Article

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 937, doi. 10.1007/s10637-012-9913-8

By:

Poklepovic, Andrew;
Youseffian, Leena;
Winning, Mary;
Birdsell, Christine;
Crosby, Nancy;
Ramakrishnan, Viswanathan;
Ernstoff, Marc;
Roberts, John

Publication type:

Article

Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 858, doi. 10.1007/s10637-012-9917-4

By:

Castro-Gamero, Angel;
Borges, Kleiton;
Moreno, Daniel;
Suazo, Veridiana;
Fujinami, Mayara;
Paula Gomes Queiroz, Rosane;
Oliveira, Harley;
Carlotti, Carlos;
Scrideli, Carlos;
Tone, Luiz

Publication type:

Article

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 959, doi. 10.1007/s10637-013-9925-z

By:

Stuurman, F.;
Voest, E.;
Awada, A.;
Witteveen, P.;
Bergeland, T.;
Hals, P.-A.;
Rasch, W.;
Schellens, J.;
Hendlisz, A.

Publication type:

Article

Therapeutic efficacy of Re-liposome in a C26 murine colon carcinoma solid tumor model.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 801, doi. 10.1007/s10637-012-9906-7

By:

Chang, Ya-Jen;
Hsu, Chin-Wei;
Chang, Chih-Hsien;
Lan, Keng-Li;
Ting, Gann;
Lee, Te-Wei

Publication type:

Article

Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 845, doi. 10.1007/s10637-012-9914-7

By:

Wilson, Peter;
LaBonte, Melissa;
Martin, Shelby;
Kuwahara, Stephanie;
El-Khoueiry, Anthony;
Lenz, Heinz-Josef;
Ladner, Robert

Publication type:

Article

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 910, doi. 10.1007/s10637-012-9895-6

By:

Yoshino, Takayuki;
Yamazaki, Kentaro;
Yamaguchi, Kensei;
Doi, Toshihiko;
Boku, Narikazu;
Machida, Nozomu;
Onozawa, Yusuke;
Asayama, Masako;
Fujino, Tadahiro;
Ohtsu, Atsushi

Publication type:

Article

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 891, doi. 10.1007/s10637-012-9887-6

By:

Dy, Grace;
Infante, Jeffrey;
Eckhardt, S.;
Novello, Silvia;
Ma, Wen;
Jones, Suzanne;
Huff, Anne;
Wang, Qiong;
Suttle, A.;
Ottesen, Lone;
Adjei, Alex;
Burris, Howard

Publication type:

Article

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 949, doi. 10.1007/s10637-012-9922-7

By:

Bundred, Nigel;
Gardovskis, Janis;
Jaskiewicz, Janusz;
Eglitis, Janis;
Paramonov, Viktor;
McCormack, Peter;
Swaisland, Helen;
Cavallin, Maria;
Parry, Tony;
Carmichael, James;
Dixon, J.

Publication type:

Article

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1016, doi. 10.1007/s10637-013-9934-y

By:

Feldman, Darren;
Einhorn, Lawrence;
Quinn, David;
Loriot, Yohann;
Joffe, Johnathan;
Vaughn, David;
Fléchon, Aude;
Hajdenberg, Julio;
Halim, Abdel-Baset;
Zahir, Hamim;
Motzer, Robert

Publication type:

Article

Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 823, doi. 10.1007/s10637-012-9908-5

By:

Lu, Frank;
Yu, Ching-Chia;
Chiu, Huei-Hsuan;
Liu, Hsingjin;
Chen, Shao-Yin;
Lin, Shufan;
Goh, Ting-Yi;
Hsu, Hsin-Chih;
Chien, Chih-Han;
Wu, Han-Chung;
Chen, Ming-Shan;
Schuyler, Scott;
Hsieh, Wu-Shiun;
Wu, Mei-Hwan;
Lu, Jean

Publication type:

Article

Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 881, doi. 10.1007/s10637-012-9920-9

By:

Heijmen, L.;
Punt, C.;
Voert, E.;
Geus-Oei, L.;
Heerschap, A.;
Bussink, J.;
Sweep, C.;
Zerbi, V.;
Oyen, W.;
Span, P.;
Boerman, O.;
Laarhoven, H.

Publication type:

Article

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1023, doi. 10.1007/s10637-013-9935-x

By:

Erba, Harry;
Sayar, Hamid;
Juckett, Mark;
Lahn, Michael;
Andre, Valerie;
Callies, Sophie;
Schmidt, Shelly;
Kadam, Sunil;
Brandt, John;
Bockstaele, Dirk;
Andreeff, Michael

Publication type:

Article

Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.

Published in:

2013

By:

Poklepovic, Andrew;
Youssefian, Leena;
Winning, Mary;
Birdsell, Christine;
Crosby, Nancy;
Ramakrishnan, Viswanathan;
Ernstoff, Marc;
Roberts, John

Publication type:

Correction Notice

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 967, doi. 10.1007/s10637-013-9929-8

By:

Naing, Aung;
Cohen, Roger;
Dy, Grace;
Hong, David;
Dyster, Lyn;
Hangauer, David;
Kwan, Rudolf;
Fetterly, Gerald;
Kurzrock, Razelle;
Adjei, Alex

Publication type:

Article

Preclinical antitumor activity of a nanoparticulate SN38.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 871, doi. 10.1007/s10637-012-9919-2

By:

Al-kasspooles, Mazin;
Williamson, Stephen;
Henry, David;
Howell, Jahna;
Niu, Fengui;
Decedue, Charles;
Roby, Katherine

Publication type:

Article

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.

Published in:

2013

By:

Rogosnitzky, Moshe;
Finegold, Milton;
McLaughlin, Patricia;
Zagon, Ian

Publication type:

Report

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1044, doi. 10.1007/s10637-013-9940-0

By:

Dreicer, Robert;
Garcia, Jorge;
Rini, Brian;
Vogelzang, Nicholas;
Srinivas, Sandy;
Somer, Bradley;
Shi, Peipei;
Kania, Marek;
Raghavan, Derek

Publication type:

Article

Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1056, doi. 10.1007/s10637-012-9909-4

By:

Borad, Mitesh;
Soman, Arundhati;
Benjamin, Martin;
Casa, Daniel;
Tembe, Waibhav;
Piper, Barbara;
Ramanathan, Ramesh;
Tibes, Raoul;
Jameson, Gayle;
Ansaldo, Karen;
Hoff, Daniel

Publication type:

Article

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 833, doi. 10.1007/s10637-012-9912-9

By:

Yan, S.;
Peek, Victoria;
Ajamie, Rose;
Buchanan, Sean;
Graff, Jeremy;
Heidler, Steven;
Hui, Yu-Hua;
Huss, Karen;
Konicek, Bruce;
Manro, Jason;
Shih, Chuan;
Stewart, Julie;
Stewart, Trent;
Stout, Stephanie;
Uhlik, Mark;
Um, Suzane;
Wang, Yong;
Wu, Wenjuan;
Yan, Lei;
Yang, Wei

Publication type:

Article

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1087, doi. 10.1007/s10637-013-9984-1

By:

Slingerland, M.;
Cerella, C.;
Guchelaar, H.;
Diederich, M.;
Gelderblom, H.

Publication type:

Article

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1001, doi. 10.1007/s10637-013-9926-y

By:

Jones, Robert;
Vuky, Jacqueline;
Elliott, Tony;
Mead, Graham;
Arranz, José;
Chester, John;
Chowdhury, Simon;
Dudek, Arkadiusz;
Müller-Mattheis, Volker;
Grimm, Marc-Oliver;
Gschwend, Jürgen;
Wülfing, Christian;
Albers, Peter;
Li, Jianguo;
Osmukhina, Anna;
Skolnik, Jeffrey;
Hudes, Gary

Publication type:

Article

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1035, doi. 10.1007/s10637-013-9936-9

By:

Moscetti, Luca;
Nelli, Fabrizio;
Fabbri, Maria;
Sperduti, Isabella;
Alesini, Daniele;
Cortesi, Enrico;
Gemma, Donatello;
Gamucci, Teresa;
Grande, Roberta;
Pavese, Ida;
Franco, Daniela;
Ruggeri, Enzo

Publication type:

Article

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 974, doi. 10.1007/s10637-013-9930-2

By:

Sharma, Sunil;
Beck, Joachim;
Mita, Monica;
Paul, Sofia;
Woo, Margaret;
Squier, Margaret;
Gadbaw, Brian;
Prince, H.

Publication type:

Article

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1008, doi. 10.1007/s10637-013-9931-1

By:

Sridhar, Srikala;
Mackenzie, Mary;
Hotte, Sebastien;
Mukherjee, Som;
Tannock, Ian;
Murray, Nevin;
Kollmannsberger, Christian;
Haider, Masoom;
Chen, Eric;
Halford, Robert;
Wang, Lisa;
Ivy, S.;
Moore, Malcolm

Publication type:

Article

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1078, doi. 10.1007/s10637-013-9977-0

By:

Belum, Viswanath;
Wu, Shenhong;
Lacouture, Mario

Publication type:

Article

Ipilimumab associated hepatitis: imaging and clinicopathologic findings.

Published in:

2013

By:

Kim, Kyung;
Ramaiya, Nikhil;
Krajewski, Katherine;
Jagannathan, Jyothi;
Tirumani, Sree;
Srivastava, Amitabh;
Ibrahim, Nageatte

Publication type:

Report

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0

By:

Infante, Jeffrey;
Novello, Silvia;
Ma, Wen;
Dy, Grace;
Bendell, Johanna;
Huff, Anne;
Wang, Qiong;
Suttle, A.;
Allen, Robert;
Xu, Chun-Fang;
Ottesen, Lone;
Burris, Howard;
Adjei, Alex

Publication type:

Article

Functional and molecular characterization of kinin B and B receptors in human bladder cancer: implication of the PI3Kγ pathway.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 812, doi. 10.1007/s10637-012-9907-6

By:

Sgnaolin, V.;
Pereira, T.;
Bogo, M.;
Zanin, R.;
Battastini, A.;
Morrone, F.;
Campos, M.

Publication type:

Article

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 918, doi. 10.1007/s10637-012-9898-3

By:

Hong, David;
Choe, Jennifer;
Naing, Aung;
Wheler, Jennifer;
Falchook, Gerald;
Piha-Paul, Sarina;
Moulder, Stacy;
George, Goldy;
Choe, Jonathan;
Strauss, Lewis;
Gallick, Gary;
Kurzrock, Razelle

Publication type:

Article

Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1051, doi. 10.1007/s10637-012-9911-x

By:

Nakajima, Keitaro;
Chiba, Koji;
Tsubamoto, Hisao;
Walsh, Jaimie;
Strawn, Laurie;
Suwa, Toshio

Publication type:

Article

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 900, doi. 10.1007/s10637-012-9893-8

By:

Lesimple, Thierry;
Edeline, Julien;
Carrothers, Timothy;
Cvitkovic, Frédérique;
Darpo, Borje;
Delord, Jean-Pierre;
Léna, Hervé;
Penel, Nicolas;
Edwards, Geoff;
Law, Kenneth;
Wanders, Jantien;
Kristensen, Allan;
Reyderman, Larisa

Publication type:

Article